Press Releases April 8, 2026 08:00 PM

Skyward Specialty Insurance Group to Host First Quarter 2026 Earnings Call Thursday, May 7th, 2026

Skyward Specialty Insurance Group schedules Q1 2026 earnings call for May 7, 2026

By Avery Klein
Share
Twitter Reddit Facebook LinkedIn
SKWD

Skyward Specialty Insurance Group, Inc. announced it will release its Q1 2026 earnings report after market close on May 6, 2026, and will host a related earnings call on May 7, 2026. The earnings report will include results from Apollo Group Holdings Ltd. Investors can access the webcast and replay via the company website. Skyward Group offers specialized insurance solutions across global specialty property and casualty markets.

Skyward Specialty Insurance Group to Host First Quarter 2026 Earnings Call Thursday, May 7th, 2026
SKWD
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Skyward Specialty Insurance Group will report Q1 2026 earnings including Apollo Group Holdings Ltd.
  • Earnings call is scheduled for May 7, 2026, accessible via webcast and conference call.
  • Company focuses on niche, complex risks in global specialty property and casualty insurance sectors.

HOUSTON , April 09, 2026 (GLOBE NEWSWIRE) -- Skyward Specialty Insurance Group, Inc (Nasdaq: SKWD) (“Skyward Group” or “the Company”), expects to issue its first quarter 2026 earnings, inclusive of Apollo Group Holdings Ltd., after market close on Wednesday, May 6th which will be available on the Company website at investors.skywardinsurance.com under Quarterly Results.

Skyward Group will host its earnings call to review the first quarter 2026 financial results on Thursday, May 7th at 10 a.m. EST.

Investors may access the live audio webcast via the link on the Company’s investor site at investors.skywardinsurance.com under Events & Presentations. Additionally, investors can access the earnings call via conference call by registering via the conference link. Users will receive dial-in information and a unique PIN to join the call upon registering.

A webcast replay will be available two hours following the call in the same location on the Company’s investor website.

About Skyward Group

Skyward Group is the holding company brand for its U.S. and Lloyds businesses, Skyward Specialty Insurance Group, Inc.® and Apollo, respectively, delivering a comprehensive suite of specialized insurance solutions across global specialty property and casualty markets. Focused on the specialty industry’s most niche, complex risks of today and the emerging challenges of tomorrow, Skyward Group leverages the forward-looking insight and disciplined execution of each organization to drive sustainable growth and long-term value for its shareholders, distribution partners, and other stakeholders.

For more information about Skyward Group, Skyward Specialty, and Apollo, please visit skywardgroup.com

Investor Contact
Skyward Group Investor Relations Dept
[email protected]

Media Contact
Haley Doughty
Skyward Specialty Insurance Group
713-935-4944
[email protected]


Risks

  • Market reaction depends on financial results, which are yet unknown at the announcement time.
  • Uncertainty regarding integrating Apollo Group Holdings Ltd.'s financials and performance impact.
  • Specialty insurance sector is sensitive to emerging risks and complex underwriting challenges, which could affect future results.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026